Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 11/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 8/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 5/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27636097 | 0.92 | HDAC1 (0.84) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6077129 | 0.90 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6078618 | 0.88 | HDAC1 (0.78) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3645712 | 0.85 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6076225 | 0.84 | HDAC1 (0.73) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3813600 | 0.84 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6078737 | 0.84 | HDAC1 (0.73) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6076890 | 0.84 | HDAC1 (0.72) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL673383 | 0.84 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL674693 | 0.83 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101279927-A | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | claimed |
| US-7098247-B2 | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | claimed |
| CN-1723192-A | Arylene-carboxylic acid (2-amino-phenyl) -amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-01-18 | — | — | CN | claimed |
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | claimed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | claimed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | claimed |
| EP-1696898-B1 | ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-8318808-B2 | Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | BAIOCCHI ROBERT A (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011143314-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | ARNO THERAPEUTICS, INC (US) | 2011-11-17 | — | — | WO | disclosed |
| US-7098247-B2 | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| CN-1723192-A | Arylene-carboxylic acid (2-amino-phenyl) -amide derivatives as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-01-18 | — | — | CN | disclosed |
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | MKI67, API5, ACIN1 | HDAC1 757/4885HDAC2 619/4885HDAC3 1558/4885 |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | HDAC1 1/4885HDAC2 5/4885HDAC3 6/4885 |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | HDAC1, HDAC4, HDAC2 | HDAC1 1/4885HDAC2 3/4885HDAC3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.